Ironwood CFO granted 136,612 restricted stock units
Ironwood Pharmaceuticals reported that Chief Financial Officer Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026.
Rhea-AI Filing Summary
Ironwood Pharmaceuticals reported that Chief Financial Officer Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. The award is structured as restricted stock units granted as an annual performance award.
The award vests in four equal installments, with 25% of the shares vesting on each approximate anniversary of the grant date. Following this grant, Martini directly holds 297,213 shares of Class A Common Stock. This is a compensation-related acquisition, not an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 136,612 | $0.00 | $0.00 |
Footnotes (1)
- F1. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did IRWD report for its CFO Gregory S. Martini?
How do the IRWD restricted stock units granted to the CFO vest over time?
Was the IRWD CFO’s recent equity award an open-market stock purchase?
What does the Form 4 transaction code A mean in the IRWD filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.